The FDA authorization Virtuoso Surgical announced on Tuesday is narrow. Its De Novo covers taking bladder lesions out in one piece, through the urethra, so a pathologist gets a better sample for diagnosing cancer. The classification the FDA created for the device carries a much broader name, electromechanical surgical systems for endoluminal surgical procedures, which covers robotic instruments passed through an endoscope into the body.
A claim sized to the published data
The indication covers urologic surgery in the bladder where a transurethral approach is appropriate, and specifically en bloc resection of bladder lesions in adults, to obtain tissue samples that help diagnose bladder cancer. Two needle-sized arms made of nested nitinol tubes sit at the tip of a standard rigid endoscope and work through the urethra. One arm lifts the tumor while the other cuts beneath it. Conventional resection usually removes a tumor in fragments, which makes the specimen harder to stage.
Virtuoso's published clinical data comes from the first 20 patients of its VIABLE study, all treated at the Chinese University of Hong Kong. In that group, 94% of removed lesions included detrusor muscle, the bladder's muscle layer, which a pathologist needs to see to stage the cancer. The study's performance goal was 60%, and Virtuoso says published studies of conventional resection report a median of about 70%. Surgeons could assess margins in 93% of malignant lesions, and the company reported no intraoperative adverse events. Its release calls the results preliminary and notes they come from a single site.
Results like these support a claim about the specimen. A claim that the robot reduces recurrence or extends survival would need patients followed for years, probably in a randomized comparison, and the authorization doesn't include that claim. Virtuoso's work in gynecology, pulmonary procedures and neurosurgery is still non-human feasibility, and those uses remain investigational.
The narrow claim also limits what Virtuoso can say when it sells. A company may promote a device only for its authorized use, so the focused launch at leading urology centers planned for 2027 will be pitched on specimen quality. Sam Chang, chief surgical officer at Vanderbilt-Ingram Cancer Center and a paid consultant to Virtuoso, said in the company's release that en bloc resection is recognized in international guidelines but is technically demanding with current instruments, and that US adoption has been very limited. A robot that makes the technique easier gives urologists a reason to try it.
What the classification order decides
A De Novo also creates a classification regulation. Later devices can reach the market through a 510(k) by showing they're substantially equivalent to a device in that classification, meaning the same intended use and either the same technology or differences that raise no new questions of safety and effectiveness. Virtuoso's device is now the reference point for anything that lands in its class, including Virtuoso's own later versions.
The order's identification paragraph describes the device type. If it speaks of endoluminal surgery in general instead of the bladder, a robot built for another part of the body at least has a classification to argue from, though a new intended use still has to be justified and may need its own De Novo. The special controls list the testing and labeling every device in the class has to meet, so whatever Virtuoso validated becomes the floor for the companies that follow. I haven't seen this order's text yet, so how broad Virtuoso's class turns out to be is still open.
I've been on the company side of that wording. Near the end of Galen Robotics' De Novo, the FDA asked what we wanted the regulation describing our device to say. We sent a paragraph, and the regulation came back matching it word for word.
Dave's take
Former FDA examiners have told me that roughly half of De Novo requests arrive effectively dead. That figure is second-hand and unpublished, and it's the reason I'd trade scope for a first authorization the evidence can carry. Virtuoso's authorization fits what its published data shows, and it puts the company first in a class whose name reaches past the bladder.
From Dave’s video library
Dave covers what has to go right between an FDA decision and a hospital's first purchase, the stretch Virtuoso enters with its planned 2027 launch.
I’m here to help you scale.
Work With DavePrefer a smaller first step? Book a $500 one-hour working session →
Dave Saunders is the founder of Base Reality Group and a Fractional CPO for product companies. He was a founder and operator at Galen Robotics, where the surgical-robotics platform earned FDA De Novo authorization in 2023, and he managed a 35-patent portfolio licensed from Johns Hopkins. He wrote Founders Who Finish and publishes The Build. More about Dave →